JAZZ Reinstated by Goldman Sachs -- Price Target Set at $337

gurufocus.com · 2026-09-24

Jazz Pharmaceuticals: Analyst Rating Update and Valuation Insights On October 3, 2023, Jazz Pharmaceuticals (JAZZ) received a reinstated 'Buy' rating from Go

TickrTrends take: Goldman Sachs has reinstated coverage of JAZZ with a price target of $337, which provides a new external benchmark for assessing the stock's fair value positioning. Since TickrTrends currently rates JAZZ as fairly valued in the Healthcare sector, investors monitoring this coverage reinstatement should track whether the Goldman Sachs target represents meaningful upside or downside relative to current market pricing. The reinstatement itself signals renewed institutional attention to the company, which could influence how the market reassesses JAZZ's valuation in the near term.

Read the full story at gurufocus.com →